These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30185083)

  • 21. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ten years of experience with the pneumococcal non-typeable
    Lecrenier N; Marijam A; Olbrecht J; Soumahoro L; Nieto Guevara J; Mungall B
    Expert Rev Vaccines; 2020 Mar; 19(3):247-265. PubMed ID: 32195602
    [No Abstract]   [Full Text] [Related]  

  • 23. Interchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review.
    Nieto Guevara J; Borys D; DeAntonio R; Guzman-Holst A; Hoet B
    Expert Rev Vaccines; 2020 Nov; 19(11):1011-1022. PubMed ID: 31751159
    [No Abstract]   [Full Text] [Related]  

  • 24. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P; Black S; Borrow R; Pearce D
    Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
    Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
    Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
    Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
    Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies.
    Hammitt LL; Akech DO; Morpeth SC; Karani A; Kihuha N; Nyongesa S; Bwanaali T; Mumbo E; Kamau T; Sharif SK; Scott JA
    Lancet Glob Health; 2014 Jul; 2(7):e397-405. PubMed ID: 25103393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
    Fitzwater SP; Chandran A; Santosham M; Johnson HL
    Pediatr Infect Dis J; 2012 May; 31(5):501-8. PubMed ID: 22327872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.
    Varghese L; Talbot L; Govender A; Zhang XH; Mungall BA
    Appl Health Econ Health Policy; 2018 Jun; 16(3):331-345. PubMed ID: 29633160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil.
    Gomez JA; Lopes de Abreu AJ; Caceres DC; Nieto J; Ortega-Barria E
    Pediatr Infect Dis J; 2019 Oct; 38(10):e260-e265. PubMed ID: 31568144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
    Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
    Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
    Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
    BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants' vaccination?
    Azzari C; Cortimiglia M; Nieddu F; Moriondo M; Indolfi G; Mattei R; Zuliani M; Adriani B; Degl'Innocenti R; Consales G; Aquilini D; Bini G; Di Natale ME; Canessa C; Ricci S; de Vitis E; Mangone G; Bechini A; Bonanni P; Pasinato A; Resti M
    Hum Vaccin Immunother; 2016; 12(2):344-50. PubMed ID: 26647277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal Pneumococcal Colonization.
    Nzenze SA; Madhi SA; Shiri T; Klugman KP; de Gouveia L; Moore DP; Karstaedt AS; Tempia S; Nunes MC; von Gottberg A
    Am J Epidemiol; 2017 Aug; 186(4):435-444. PubMed ID: 28482004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease.
    Izurieta P; Nieto Guevara J
    Hum Vaccin Immunother; 2022 Dec; 18(1):1872341. PubMed ID: 33605846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects.
    Davis SM; Deloria-Knoll M; Kassa HT; O'Brien KL
    Vaccine; 2013 Dec; 32(1):133-45. PubMed ID: 23684824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study.
    Szenborn L; Osipova IV; Czajka H; Kharit SM; Jackowska T; François N; Habib MA; Borys D
    Vaccine; 2017 Sep; 35(40):5331-5338. PubMed ID: 28866290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
    Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.